Celltrion Bags FDA Approval For High-Concentration Humira Rival
Yuflyma, Ninth US Adalimumab Biosimilar, Will Be Marketed Directly By Korean Firm
Celltrion USA has won US FDA approval for its Yuflyma 100mg/ml adalimumab biosimilar, making it the third high-concentration version approved in the US and the ninth Humira rival overall.
